| CORP. ACTIVITY | Co. already conducts small-scale commercial cGMP manufacturing for customers--particularly now that it has opened the second site--and one way for the company to expand successfully, would be to develop its own products, perhaps active ingredients for the generic pharmaceutical industry |
| CORP. FOCUS |
Co.'s main business is fee-for-service-based chemical process development and multistep organic synthesis for the pharmaceutical industry. Co. says he could manage the company under this model until it reaches about 50 employees. "After that, it would lose its identity," he believes. |
| CORP. INFORMATION |
Co. strives to finance his company's expansion through an evenly divided combination of its own cash, guaranteed contracts, and bank loans. Co which opened a new facility in March, "will not fall into the trap of constructing grandiose greenfield sites with the hope that clients will come." "We are taking a pragmatic approach with steady, controlled growth." The company employs 25 people, five of whom are Ph.D. chemists. |
| SALES VALUE | 100% growth in each of the past two years, reaching $8.6 million in 2001. |
| UPDATE | 06.02 |
| COMPANY | This data is not available for free |
| CONTACT | This data is not available for free |
| CORP. HISTORIC | Co formed in 1999 |
| LITERATURE REF. | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |